Table 3.
Treatment-related adverse events.
| Adverse event | Maximum grade | ||||
|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | Total | |
| Abdominal pain | 3 | 0 | 0 | 0 | 3 |
| Alanine aminotransferase—increased | 4 | 0 | 1 | 0 | 5 |
| Alkaline phosphatase—increased | 2 | 0 | 1 | 0 | 3 |
| Anorexia | 1 | 0 | 0 | 0 | 1 |
| Anxiety | 1 | 1 | 0 | 0 | 2 |
| Arthralgia | 1 | 0 | 0 | 0 | 1 |
| Arthritis | 0 | 0 | 1 | 0 | 1 |
| Ascites | 0 | 0 | 1 | 0 | 1 |
| Aspartate aminotransferase—increased | 3 | 0 | 1 | 0 | 4 |
| Blood bilirubin increased | 2 | 0 | 0 | 0 | 2 |
| CPK increased | 2 | 0 | 0 | 0 | 2 |
| Cholecystitis | 0 | 0 | 1 | 0 | 1 |
| Cough | 1 | 0 | 0 | 0 | 1 |
| Creatinine increased | 0 | 1 | 0 | 0 | 1 |
| Dizziness | 1 | 0 | 0 | 0 | 1 |
| Dry mouth | 0 | 1 | 0 | 0 | 1 |
| Dyspnea | 0 | 1 | 0 | 0 | 1 |
| Eosinophilia | 1 | 0 | 0 | 0 | 1 |
| Fatigue | 7 | 3 | 0 | 0 | 10 |
| Fever | 1 | 0 | 0 | 0 | 1 |
| Headache | 1 | 0 | 0 | 0 | 1 |
| Hyperglycemia | 1 | 0 | 0 | 0 | 1 |
| Hyperthyroidism | 1 | 1 | 0 | 0 | 2 |
| Hypokalemia | 1 | 1 | 1 | 0 | 3 |
| Hyponatremia | 1 | 0 | 1 | 0 | 2 |
| Hypothyroidism | 0 | 4 | 0 | 0 | 4 |
| Injection site reaction | 0 | 21 | 0 | 0 | 21 |
| Lipase increased | 2 | 1 | 0 | 1 | 4 |
| Lymphopenia | 3 | 0 | 0 | 0 | 3 |
| Mucositis oral | 0 | 1 | 0 | 0 | 1 |
| Nausea | 3 | 1 | 0 | 0 | 4 |
| Neutropenia | 0 | 0 | 1 | 0 | 1 |
| Pain | 0 | 1 | 0 | 0 | 1 |
| Pain in extremity | 1 | 4 | 0 | 0 | 5 |
| Thrombocytopenia | 2 | 0 | 0 | 0 | 2 |
| Rash maculo-papular | 3 | 0 | 0 | 0 | 3 |
| Serum amylase increased | 2 | 0 | 1 | 0 | 3 |
| Sinus bradycardia | 1 | 0 | 0 | 0 | 1 |
| Vomiting | 1 | 0 | 0 | 0 | 1 |